查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1625205

到 2030 年In Silico臨床試驗市場預測：按類型、模擬類型、治療方法、技術、應用、最終用戶和地區進行的全球分析

In Silico Clinical Trials Market Forecasts to 2030 - Global Analysis By Type, Simulation Type, Therapeutic, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 預測，到 2024 年，全球In Silico臨床試驗市場規模將達到 36 億美元，預計在預測期內複合年成長率為 8.4%，到 2000 年將達到 58 億美元。

In Silico臨床試驗使用電腦模擬和建模來重建人類生物學並預測醫療干預措施的有效性。這些虛擬試驗使用大量患者資料、生物模型和計算演算法來模擬藥物、治療方法或設備在現實臨床環境中的工作方式。透過取代或減少對傳統體內測試的需求，電腦模擬測試提供了一種更快、更具成本效益的方法，可以在臨床引入之前評估治療的安全性和有效性，並提供合乎道德的替代方案。

根據歐洲藥品管理局（歐盟）統計，歐盟/歐洲經濟區每年批准超過 4,000 項臨床試驗，其中 60% 由製藥公司贊助，40% 由非商業贊助商贊助。印度臨床試驗註冊中心 (CTRI) 的數據顯示，2021 年印度核准了100 多項國際臨床試驗，這是自 2013 年以來的最高數量。

對更安全藥物的需求不斷成長

市場開發對更安全藥物的需求不斷成長，這是由於對更高效、更具成本效益和合乎道德的藥物開發流程的需求所推動的。In Silico，使用先進的計算模型，透過在實際臨床試驗之前預測藥物療效、毒性和患者反應，為傳統臨床試驗提供更安全的替代方案。這種方法可以加快藥物核准速度，降低風險，最大限度地減少對動物和人體測試的依賴，並滿足監管和公共衛生目標。

難以獲得高品質資料

市場上高品質資料的有限性阻礙了預測模型的準確性和可靠性。資料不足或偏差可能會為模擬帶來缺陷，從而導致對藥物療效、安全性和患者反應的錯誤預測。這削弱了In Silico臨床試驗取代傳統方法的潛力，減緩了藥物開發，增加了風險，並可能導致監管部門核准延遲或不批准新治療方法。

計算建模和人工智慧的進展

計算建模和人工智慧的發展透過提高藥物開發的準確性和效率正在徹底改變市場。人工智慧演算法分析大量資料集來預測藥物交互作用、患者反應和潛在副作用。改進的計算模型可以模擬複雜的生物系統並減少對傳統臨床試驗的依賴。這些創新可以實現更快、更準確的藥物測試，最佳化臨床結果和安全性，同時降低成本並加快新療法的上市時間。

監管和道德的不確定性

市場中的監管和道德不確定性對採用提出了重大挑戰。藥物測試中計算模型的使用缺乏明確的指南可能會延遲核准過程並增加合規風險。此外，有關資料隱私、病患同意和模型透明度的倫理問題可能會阻礙人們對這些技術的信心，減緩進展，並限制其取代傳統臨床試驗方法的潛力。

COVID-19 的影響：

COVID-19 大流行凸顯了對更快、更有效的藥物開發方法的需求，並加速了In Silico臨床試驗的採用。由於傳統的臨床試驗面臨中斷，計算模型對於快速藥物測試和疫苗開發變得至關重要。這次疫情凸顯了虛擬模擬在減少臨床試驗時間、成本和對物理互動的依賴方面的優勢，刺激了市場的進一步投資和創新。

預計臨床前測試領域在預測期內將是最大的。

預計臨床前測試領域將在預測期內佔據最大的市場佔有率。這些虛擬試驗使研究人員能夠預測藥物功效、安全性和藥物動力學，並幫助識別潛在風險、副作用和最佳劑量。透過利用人工智慧、機器學習和其他預測技術，In Silico臨床前測試可以減少與傳統動物和人體測試相關的成本、時間和倫理問題，加速藥物開發並提高成功率。

機器學習領域預計在預測期內複合年成長率最高

預計機器學習領域在預測期內將表現出最高的複合年成長率。這些演算法處理大量資料集來預測患者反應、確定最佳劑量策略並模擬試驗結果，從而顯著縮短時間。該技術還將增強決策、提高測試準確性並支援個人化醫療。因此，機器學習正成為加速藥物開發和推動更有效率、資料主導的臨床研究方法的重要工具。

比最大的地區

由於計算建模、人工智慧和巨量資料分析的進步，預計北美地區在預測期內將佔據最大的市場佔有率。這些虛擬模擬透過提高效率、降低成本和最小化風險，正在徹底改變藥物開發。監管接受度的提高、個人化醫療需求的增加以及對精準醫療保健的日益關注等關鍵因素正在促進該地區的市場擴張。

複合年成長率最高的地區：

在計算模型進步的推動下，亞太地區預計將在預測期內實現最高成長率。人工智慧 (AI)、機器學習 (ML) 和巨量資料擴大融入In Silico臨床試驗市場。這些技術可以實現更好的預測模型、提高測試準確性並降低開發成本。此外，生物創業公司數量的增加以及政府對醫療保健數位轉型的支持也推動了市場成長。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場公司的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭標基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球In Silico臨床試驗市場：按類型

  • 臨床前測試
  • 臨床試驗
  • 上市後測試
  • 法規遵從性測試
  • 疾病模型測試
  • 其他類型

第6章全球In Silico臨床試驗市場：依模擬類型

  • 生理模擬
  • 毒理學模擬
  • 疾病模型
  • 基於群體的模擬
  • 虛擬病人模擬

第7章全球In Silico臨床試驗市場：依治療方法

  • 腫瘤學
  • 感染疾病
  • 心臟病學
  • 神經病學
  • 糖尿病
  • 其他治療方法

第8章全球In Silico臨床試驗市場：依技術分類

  • 計算生物學
  • 人工智慧
  • 機器學習
  • 系統生物學
  • 其他技術

第9章全球In Silico臨床試驗市場：依應用分類

  • 藥物發現與開發
  • 醫療設備開發
  • 數位健康技術
  • 個人化醫療
  • 其他用途

第 10 章全球In Silico臨床試驗市場：依最終使用者分類

  • 製藥和生物技術公司
  • 學術機構
  • 合約研究組織（CRO）
  • 監管機構
  • 其他最終用戶

第11章全球In Silico臨床試驗市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第12章 主要進展

  • 合約、夥伴關係、合作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第13章 公司概況

  • Novadiscovery
  • Dassault Systemes
  • GNS Healthcare
  • Clarivate
  • Evotec
  • Abzena Ltd.
  • PerkinElmer Inc.
  • Schrodinger, Inc.
  • Selvita
  • Tracxn Technologies
  • WuXi AppTec
  • Hoffmann-La Roche
  • Mars
  • PYC Therapeutics
  • Immatics
Product Code: SMRC28160

According to Stratistics MRC, the Global In Silico Clinical Trials Market is accounted for $3.6 billion in 2024 and is expected to reach $5.8 billion by 200 growing at a CAGR of 8.4% during the forecast period. In silico clinical trials are the use of computer simulations and modeling to replicate human biology and predict the effects of medical interventions. These virtual trials use vast amounts of patient data, biological models, and computational algorithms to simulate how drugs, therapies, or devices would perform in real-world clinical settings. By replacing or reducing the need for traditional in vivo trials, in silico trials offer a faster, cost-effective, and ethical alternative for evaluating the safety and efficacy of treatments before clinical implementation.

According to the European Medicines Agency - European Union, in the EU / EEA, more than 4,000 clinical trials are authorised each year, of which 60% of clinical trials are sponsored by the pharma industry and 40% by non-commercial sponsors. As per the Clinical Trials Registry India (CTRI), India approved over 100 global clinical trials in 2021, the highest since 2013.

Market Dynamics:

Driver:

Growing demand for safer drugs

The growing demand for safer drugs in the market is driven by the need for more efficient, cost-effective, and ethical drug development processes. In silico trials, using advanced computational models, offer a safer alternative to traditional clinical trials by predicting drug efficacy, toxicity, and patient responses before real-world testing. This approach accelerates drug approval, reduces risks, and minimizes the reliance on animal and human testing, aligning with regulatory and public health goals.

Restraint:

Limited availability of high-quality data

The limited availability of high-quality data in the market hampers the accuracy and reliability of predictive models. Inadequate or biased data can lead to flawed simulations, resulting in incorrect predictions about drug efficacy, safety, or patient responses. This undermines the potential of in silico trials to replace traditional methods, slowing down drug development, increasing risks, and potentially leading to delayed or failed regulatory approvals for new treatments.

Opportunity:

Advances in computational modeling and AI

Advances in computational modeling and AI are revolutionizing market by enhancing the accuracy and efficiency of drug development. AI algorithms analyze vast datasets to predict drug interactions, patient responses, and potential side effects. Improved computational models simulate complex biological systems, reducing reliance on traditional trials. These innovations enable faster, more precise drug testing, optimizing clinical outcomes and safety while lowering costs and accelerating time-to-market for new treatments.

Threat:

Regulatory and ethical uncertainty

Regulatory and ethical uncertainty in the market poses a significant challenge to widespread adoption. The lack of clear guidelines on the use of computational models in drug testing can delay approval processes and increase compliance risks. Additionally, ethical concerns about data privacy, patient consent, and model transparency may hinder trust in these technologies, slowing progress and limiting their potential to replace traditional clinical trial methods effectively.

Covid-19 Impact:

The COVID-19 pandemic accelerated the adoption of In Silico Clinical Trials by highlighting the need for faster, more efficient drug development methods. With traditional trials facing disruptions, computational models became crucial for rapid drug testing and vaccine development. The pandemic emphasized the benefits of virtual simulations in reducing trial timelines, costs, and reliance on physical interactions, driving further investment and innovation in the market.

The preclinical trials segment is expected to be the largest during the forecast period

The preclinical trials segment is expected to account for the largest market share during the projection period. These virtual trials enable researchers to predict drug efficacy, safety, and pharmacokinetics, helping to identify potential risks, side effects, and optimal dosages. By utilizing AI, machine learning, and other predictive technologies, in silico preclinical trials reduce the cost, time, and ethical concerns associated with traditional animal and human studies, accelerating drug development and improving success rates.

The machine learning segment is expected to have the highest CAGR during the forecast period

The machine learning segment is expected to have the highest CAGR during the extrapolated period. These algorithms process vast datasets to predict patient responses, identify optimal dosing strategies, and simulate trial outcomes, significantly reducing the time. This technology also enhances decision-making, improves trial accuracy, and supports personalized medicine. As a result, ML is becoming a crucial tool in accelerating drug development and advancing more efficient, data-driven clinical research methodologies.

Region with largest share:

North America region is projected to account for the largest market share during the forecast period driven by advancements in computational modeling, artificial intelligence, and big data analytics. These virtual simulations are revolutionizing drug development by enhancing efficiency, reducing costs, and minimizing risks. Key factors such as increasing regulatory acceptance, a rising demand for personalized medicine, and a growing focus on precision healthcare contribute to the market's expansion in the region.

Region with highest CAGR:

Asia Pacific is expected to register the highest growth rate over the forecast period driven by advancements in computational models. Artificial Intelligence (AI), Machine Learning (ML), and Big Data are being increasingly integrated into the in silico clinical trials market. These technologies enable better prediction models, improve trial accuracy, and reduce development costs. Additionally, the rise in biotech startups, along with government support for digital transformation in healthcare, is helping the market grow.

Key players in the market

Some of the key players in In Silico Clinical Trials market include Novadiscovery, Dassault Systemes, GNS Healthcare, Clarivate, Evotec, Abzena Ltd., PerkinElmer Inc., Schrodinger, Inc., Selvita, Tracxn Technologies, WuXi AppTec, Hoffmann- La Roche, Mars, PYC Therapeutics and Immatics.

Key Developments:

In October 2024, Dassault Systemes announced the availability of the world's first guide for the medical device industry that outlines how to use virtual twins to accelerate clinical trials. The in silico clinical trial "ENRICHMENT Playbook" marks a significant advancement in the integration of virtual twins into the regulatory process in response to needs for improved patient safety, regulatory compliance, and pace of innovation.

In July 2024, Clarivate Plc announced the launch of its new OFF-X platform. It delivers critical drug and target safety information to proactively identify risks. Integrated with Cortellis Drug Discovery Intelligence(TM), OFF-X(TM) provides a comprehensive, one-stop resource for drug safety information, streamlining processes, increasing efficiencies and delivering a competitive advantage.

Types Covered:

  • Preclinical Trials
  • Clinical Trials
  • Post-Market Trials
  • Regulatory Compliance Trials
  • Disease Modeling Trials
  • Other Types

Simulation Types Covered:

  • Physiological Simulations
  • Toxicology Simulations
  • Disease Models
  • Population-Based Simulations
  • Virtual Patient Simulations

Therapeutics Covered:

  • Oncology
  • Infectious Disease
  • Cardiology
  • Neurology
  • Diabetes
  • Other Therapeutics

Technologies Covered:

  • Computational Biology
  • Artificial Intelligence
  • Machine Learning
  • Systems Biology
  • Other Technologies

Applications Covered:

  • Drug Discovery and Development
  • Medical Device Development
  • Digital Health Technologies
  • Personalized Medicine
  • Other Applications

End Users Covered:

  • Pharmaceutical and Biotechnology Companies
  • Academic Institutions
  • Contract Research Organizations (CROs)
  • Regulatory Authorities
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global In Silico Clinical Trials Market, By Type

  • 5.1 Introduction
  • 5.2 Preclinical Trials
  • 5.3 Clinical Trials
  • 5.4 Post-Market Trials
  • 5.5 Regulatory Compliance Trials
  • 5.6 Disease Modeling Trials
  • 5.7 Other Types

6 Global In Silico Clinical Trials Market, By Simulation Type

  • 6.1 Introduction
  • 6.2 Physiological Simulations
  • 6.3 Toxicology Simulations
  • 6.4 Disease Models
  • 6.5 Population-Based Simulations
  • 6.6 Virtual Patient Simulations

7 Global In Silico Clinical Trials Market, By Therapeutic

  • 7.1 Introduction
  • 7.2 Oncology
  • 7.3 Infectious Disease
  • 7.4 Cardiology
  • 7.5 Neurology
  • 7.6 Diabetes
  • 7.7 Other Therapeutics

8 Global In Silico Clinical Trials Market, By Technology

  • 8.1 Introduction
  • 8.2 Computational Biology
  • 8.3 Artificial Intelligence
  • 8.4 Machine Learning
  • 8.5 Systems Biology
  • 8.6 Other Technologies

9 Global In Silico Clinical Trials Market, By Application

  • 9.1 Introduction
  • 9.2 Drug Discovery and Development
  • 9.3 Medical Device Development
  • 9.4 Digital Health Technologies
  • 9.5 Personalized Medicine
  • 9.6 Other Applications

10 Global In Silico Clinical Trials Market, By End User

  • 10.1 Introduction
  • 10.2 Pharmaceutical and Biotechnology Companies
  • 10.3 Academic Institutions
  • 10.4 Contract Research Organizations (CROs)
  • 10.5 Regulatory Authorities
  • 10.6 Other End Users

11 Global In Silico Clinical Trials Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Novadiscovery
  • 13.2 Dassault Systemes
  • 13.3 GNS Healthcare
  • 13.4 Clarivate
  • 13.5 Evotec
  • 13.6 Abzena Ltd.
  • 13.7 PerkinElmer Inc.
  • 13.8 Schrodinger, Inc.
  • 13.9 Selvita
  • 13.10 Tracxn Technologies
  • 13.11 WuXi AppTec
  • 13.12 Hoffmann- La Roche
  • 13.13 Mars
  • 13.14 PYC Therapeutics
  • 13.15 Immatics

List of Tables

  • Table 1 Global In Silico Clinical Trials Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global In Silico Clinical Trials Market Outlook, By Type (2022-2030) ($MN)
  • Table 3 Global In Silico Clinical Trials Market Outlook, By Preclinical Trials (2022-2030) ($MN)
  • Table 4 Global In Silico Clinical Trials Market Outlook, By Clinical Trials (2022-2030) ($MN)
  • Table 5 Global In Silico Clinical Trials Market Outlook, By Post-Market Trials (2022-2030) ($MN)
  • Table 6 Global In Silico Clinical Trials Market Outlook, By Regulatory Compliance Trials (2022-2030) ($MN)
  • Table 7 Global In Silico Clinical Trials Market Outlook, By Disease Modeling Trials (2022-2030) ($MN)
  • Table 8 Global In Silico Clinical Trials Market Outlook, By Other Types (2022-2030) ($MN)
  • Table 9 Global In Silico Clinical Trials Market Outlook, By Simulation Type (2022-2030) ($MN)
  • Table 10 Global In Silico Clinical Trials Market Outlook, By Physiological Simulations (2022-2030) ($MN)
  • Table 11 Global In Silico Clinical Trials Market Outlook, By Toxicology Simulations (2022-2030) ($MN)
  • Table 12 Global In Silico Clinical Trials Market Outlook, By Disease Models (2022-2030) ($MN)
  • Table 13 Global In Silico Clinical Trials Market Outlook, By Population-Based Simulations (2022-2030) ($MN)
  • Table 14 Global In Silico Clinical Trials Market Outlook, By Virtual Patient Simulations (2022-2030) ($MN)
  • Table 15 Global In Silico Clinical Trials Market Outlook, By Therapeutic (2022-2030) ($MN)
  • Table 16 Global In Silico Clinical Trials Market Outlook, By Oncology (2022-2030) ($MN)
  • Table 17 Global In Silico Clinical Trials Market Outlook, By Infectious Disease (2022-2030) ($MN)
  • Table 18 Global In Silico Clinical Trials Market Outlook, By Cardiology (2022-2030) ($MN)
  • Table 19 Global In Silico Clinical Trials Market Outlook, By Neurology (2022-2030) ($MN)
  • Table 20 Global In Silico Clinical Trials Market Outlook, By Diabetes (2022-2030) ($MN)
  • Table 21 Global In Silico Clinical Trials Market Outlook, By Other Therapeutics (2022-2030) ($MN)
  • Table 22 Global In Silico Clinical Trials Market Outlook, By Technology (2022-2030) ($MN)
  • Table 23 Global In Silico Clinical Trials Market Outlook, By Computational Biology (2022-2030) ($MN)
  • Table 24 Global In Silico Clinical Trials Market Outlook, By Artificial Intelligence (2022-2030) ($MN)
  • Table 25 Global In Silico Clinical Trials Market Outlook, By Machine Learning (2022-2030) ($MN)
  • Table 26 Global In Silico Clinical Trials Market Outlook, By Systems Biology (2022-2030) ($MN)
  • Table 27 Global In Silico Clinical Trials Market Outlook, By Other Technologies (2022-2030) ($MN)
  • Table 28 Global In Silico Clinical Trials Market Outlook, By Application (2022-2030) ($MN)
  • Table 29 Global In Silico Clinical Trials Market Outlook, By Drug Discovery and Development (2022-2030) ($MN)
  • Table 30 Global In Silico Clinical Trials Market Outlook, By Medical Device Development (2022-2030) ($MN)
  • Table 31 Global In Silico Clinical Trials Market Outlook, By Digital Health Technologies (2022-2030) ($MN)
  • Table 32 Global In Silico Clinical Trials Market Outlook, By Personalized Medicine (2022-2030) ($MN)
  • Table 33 Global In Silico Clinical Trials Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 34 Global In Silico Clinical Trials Market Outlook, By End User (2022-2030) ($MN)
  • Table 35 Global In Silico Clinical Trials Market Outlook, By Pharmaceutical and Biotechnology Companies (2022-2030) ($MN)
  • Table 36 Global In Silico Clinical Trials Market Outlook, By Academic Institutions (2022-2030) ($MN)
  • Table 37 Global In Silico Clinical Trials Market Outlook, By Contract Research Organizations (CROs) (2022-2030) ($MN)
  • Table 38 Global In Silico Clinical Trials Market Outlook, By Regulatory Authorities (2022-2030) ($MN)
  • Table 39 Global In Silico Clinical Trials Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.